|
|
Article: Tranzyme Enters QBI Deal, Targets Neurosensory Drugs.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Tranzyme Inc.'s trio of gene expression methods and drug discovery technologies netted it another collaboration - this one a licensing deal and multiyear research partnership with Quark Biotech Inc.
Privately held Tranzyme is granting QBI a nonexclusive worldwide license to its three-part technology package that includes TExT, for protein expression; TranzVector, for gene transfer; and TranzAssay, for development and drug discovery.
"This is the most significant deal the company has done," said Vipin Garg, president and CEO of Birmingham, Ala.-based Tranzyme. "We've come to a point where we've progressed from short-term ...
Related newspaper, magazine, and journal articles:
|
|
Article: BioWorld Today Introduces Tomorrow's News Today.
BIOWORLD Today;
January 22, 2008 ;
356 words
...BioWorld Today online subscribers will now receive the BioWorld Today Midday Report each weekday afternoon featuring topics you can look forward to in the next issue of BioWorld Today. The BioWorld Today Midday Report gives you a ...
|
|